Business
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.
About this update from Generate Biomedicines, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":523,"olType":false},{"type":"text","content":"SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.","length":250,"tagName":"p"},{"type":"image","alt":"Generate:Biomedicines Logo (PRNewsfoto/Generate:Biomedicines)","displaySize":"","headline":null,"caption":"Generate:Biomedicines Logo (PRNewsfoto/Generate:Biomedicines)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f3eaeb751f3b392a1a5c22a9c87ed541"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1ZpNrBYKtIoHj08Kh8FqZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1Mw--/https://media.zenfs.com/en/prnewswire.com/f3eaeb751f3b392a1a5c22a9c87ed541","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/2594219/GENERATE_BIOMEDICINES__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform," said Mike Nally, chief executive officer of Generate Biomedicines, Inc. "We are advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. In oncology, we expect to progress two clinical trials this year with GB-4362, an MMAE neutralizer, and GB-5267, a MUC16 CAR T developed with Roswell Park. Together, these ...